Toll-like receptor 9 agonists as cancer therapeutics

被引：53
|
作者：
Holtick, Udo [1 ,2 ]
Scheulen, Max E. [3 ]
von Bergwelt-Baildon, Michael S. [1 ,2 ]
Weihrauch, Martin R. [1 ,2 ]
机构：
[1] Univ Cologne, Dept Internal Med 1, D-50924 Cologne, Germany
[2] Univ Cologne, Lab Transplantat & Tumor Immunol, Max Eder Grp, D-50924 Cologne, Germany
[3] Univ Essen Gesamthsch, W German Canc Ctr, Dept Med Canc Res, Essen, Germany
来源：
EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2011年 / 20卷 / 03期
关键词：
cancer; immunotherapy; TLR9; agonists; vaccine; BACTERIAL CPG-DNA; PHASE-II TRIAL; NF-KAPPA-B; T-CELLS; IMMUNOSTIMULATORY ACTIVITY; DENDRITIC CELLS; MOLECULAR-PATTERNS; ANTITUMOR-ACTIVITY; INNATE IMMUNITY; GROWTH-FACTOR;
D O I：
10.1517/13543784.2011.553187
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Areas covered: This review summarizes TLR9 signaling and the impact of TLR9 agonists on the immune response. The most recent experimental and clinical data are analyzed as well as the development of new TLR9 agonists in current clinical trials. Expert opinion: Application of TLR9 agonists, in particular, combination strategies with chemo- or radiotherapy seem a promising and efficient immunotherapeutic approach in cancer patients even with refractory disease. Simultaneous application of TLR9 agonists aims at supporting the patient's immune response and overcoming specific immunosuppressant strategies developed by tumors. Combinatory approaches of the future might also seek for synergism of TLR9 agonists with other immunomodulatory strategies such as B-cell activation using the CD40--CD40L system.
引用
收藏
页码：361 / 372
页数：12
相关论文
共 50 条
  • [1] Toll-Like Receptor 9 Agonists in Cancer
    Karapetyan, Lilit
    Luke, Jason J.
    Davar, Diwakar
    ONCOTARGETS AND THERAPY, 2020, 13 : 10039 - 10060
  • [2] Toll-Like Receptor 9 Agonists for Cancer Therapy
    Melisi, Davide
    Frizziero, Melissa
    Tamburrino, Anna
    Zanotto, Marco
    Carbone, Carmine
    Piro, Geny
    Tortora, Giampaolo
    BIOMEDICINES, 2014, 2 (03) : 211 - 228
  • [3] Clinical setbacks for toll-like receptor 9 agonists in cancer
    Schmidt, Charlie
    NATURE BIOTECHNOLOGY, 2007, 25 (08) : 825 - 826
  • [4] Clinical setbacks for toll-like receptor 9 agonists in cancer
    Charlie Schmidt
    Nature Biotechnology, 2007, 25 : 825 - 826
  • [5] Toll-like receptor agonists and cancer
    不详
    NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (07) : 511 - 511
  • [6] Toll-like receptor 9 (TLR9) agonists in the treatment of cancer
    A M Krieg
    Oncogene, 2008, 27 : 161 - 167
  • [7] Toll-like receptor 9 (TLR9) agonists in the treatment of cancer
    Krieg, A. M.
    ONCOGENE, 2008, 27 (02) : 161 - 167
  • [8] Toll-like receptor agonists in cancer therapy
    Adams, Sylvia
    IMMUNOTHERAPY, 2009, 1 (06) : 949 - 964
  • [9] Toll-like receptor agonists in adjuvant immunotherapy for cancer
    Farkas, A.
    Urosevic, M.
    Dummer, R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 : S21 - S21
  • [10] Toll-like receptor agonists as cancer vaccine adjuvants
    Jeon, Donghwan
    Hill, Ethan
    Mcneel, Douglas G.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
12345